key: cord-0965668-s609sutd authors: Aalberg, Jeffrey J; Collins, Timothy P; Dobrow, Ethan M title: Axillary lymphadenopathy in a renal cell carcinoma patient after COVID-19 Vaccination date: 2021-06-11 journal: Radiol Case Rep DOI: 10.1016/j.radcr.2021.05.031 sha: 914cb3c956715807b0ac4432134f346a1dca1040 doc_id: 965668 cord_uid: s609sutd The distribution of the novel Covid-19 vaccines has been on a scale as unprecedented as the pandemic itself. While the vaccines promise to greatly reduce the spread and impact of the disease, encountering side-effects in clinical practice may pose diagnostic dilemmas. In this case report, we describe a patient with known metastatic renal cell carcinoma who presents with axillary lymphadenopathy found on PET/CT imaging after receiving a Covid-19 vaccine, which was subsequently confirmed to be reactive lymphadenopathy following biopsy. The Coronavirus Disease 2019 (COVID-19) pandemic has spread world-wide with over 119 million infected worldwide and over 2.6 million dead at the time of publication [1] . Three vaccines have been approved for use in the United States. Two of these, the "Moderna" and "Pfizer-BioNTech" vaccines are mRNA vaccines encoding for the coronavirus "spike protein," a glycoprotein which is necessary for cellular entry. [2] . As of publication, over 107 million people in the U.S. have received at least one dose of these vaccines [3] . standardized uptake value (SUV) of 9.7 ( Fig. 1 ) , with additional sub-centimeter left axillary lymph nodes with a maximum SUV of 4.1. The scan additionally revealed an unchanged 0.8 lingular lung nodule with a SUV of 3.1, a 0.7cm lower lobe nodule with SUV increased to 4.0 from 1.9, a decrease in psoas avidity to 10.1 from 32.2, and focal avid FDG uptake in the left lateral deltoid muscle ( Fig. 2 ) . Ultrasound guided fine-needle aspiration biopsy of the left axillary node was performed after discussion with the patient, because of his known history of metastatic disease to lung and bone, with variable PET activity to known metastatic lesions in the lung ( Fig. 3 ). Cytopathology demonstrated a polymorphous lymphoid population compatible with a reactive lymph node and was negative for metastatic carcinoma ( Fig. 4 ). This case report describes a patient with known metastatic clear cell renal cell carcinoma who presents with increased avidity on PET/CT imaging in the axilla ipsilateral to the arm in which a COVID-19 vaccine was administered. Subsequent biopsy demonstrated reactive hyperplasia. Lymphadenopathy following COVID-19 vaccination is a common event. In clinical trials of the Moderna vaccine, 10.2% of patients had any degree of lymph node enlargement or axillary fullness after the first dose as compared to 4.8% in the placebo group and 14.0% after the second dose vs 3.9% placebo. These rates vary with age, with those above 65 reporting lymphadenopathy more infrequently. Grade 3 lymphadenopathy, defined as preventing daily activity or necessitating the use of prescription pain relievers occurred in 0.3% of patients after the first dose (0.2% placebo) and 0.5% after the second dose (0.1% placebo) [4] . Data is less detailed for the Pfizer-BioNTech vaccine which reported a 0.3% rate of any lymphadenopathy [5] . The COVID-19 mRNA vaccines are not unique in their ability to provoke lymph node enlargement. It is a rare, but known effect of other vaccines, including the bacille Calmette-Guerin, Smallpox, Influenza, HPV, and anthrax vaccines [6] [7] [8] [9] [10] . The high incidence of lymphadenopathy after COVID-19 vaccination in particular poses a challenge to radiographers and other providers who may discover subclinical lymph node enlargement on imaging. This incidental finding lends itself to a differential which includes not only reactive hyperplasia, but also malignancy, systemic infections, and local injury. This problem has been highlighted in several recent case reports and case series. The majority of these reports describe lymphadenopathy discovered in the setting of routine mammography [ 11 ,12 ] . However, there have been a small number of additional reports of patients imaged for cancer staging or follow-up in which adenopathy is discovered, including in metastatic melanoma, invasive ductal carcinoma, and liposarcoma [12] [13] [14] . Decisions regarding management in the latter of these 2 scenarios must take into account the higher pre-test probability of metastatic spread to a node. Given the diagnostic uncertainty of post-vaccine lymphadenopathy, it is recommended that when possible, patients postpone routine screenings until 4-6 weeks after the completion of their vaccination course [ 15 ,16 ] . In situations where this was not possible and lymphadenopathy is discovered after vaccination, the course of management depends on the clinicians determination of the likelihood that the lymphadenopathy is related to the vaccine. If lymphadenopathy is discovered within 6 weeks of vaccination, is ipsilateral to the site of vaccine injection, and in a patient with no history of cancer, then it may be assumed to be a result of the vaccine. The patient should be reassessed in 6 weeks to confirm resolution. If it persists for more than 6 weeks, is on the contralateral side to the vaccine, or is in the setting of known cancer, then biopsy should be considered [15] [16] [17] . As COVID-19 vaccination becomes more accessible, the rate of discovery of incidental lymphadenopathy will become more common. Care must be taken in clinical decision making to avoid the overuse of biopsies or further imaging. Physicians need to be aware of patients' vaccine status and the location of the injection when interpreting radiologic images and performing physical exams in order to risk-stratify findings in an appropriate manner. The authors of this report confirm that informed consent for publication of their case was obtained from the patient. An mRNA vaccine against SARS-CoV-2-preliminary report Systemic REACTIONS, adverse events, and serious Adverse EVENTS: Moderna Covid-19 Vaccine Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Complications associated with the bacille Calmette-Guerin vaccination in Ireland Adverse events following HPV vaccination Smallpox vaccination in 2003: key information for clinicians Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination Coronavirus disease (COVID-19) vaccination associated axillary adenopathy: imaging findings and follow-up recommendations in 23 women Unilateral axillary Adenopathy in the setting of COVID-19 vaccine Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma The Canadian Society of Breast Imaging/Canadian Association of Radiologists' recommendations for the management of axillary adenopathy in patients with recent COVID-19 vaccination Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: Radiology scientific expert panel Unilateral lymphadenopathy post COVID-19 vaccination: a practical management plan for radiologists across specialties